Effect of creatine and pioglitazone on Hk-2 cell line cisplatin nephrotoxicity

Renal Failure

Volumn 36, Issue 7, 2014, Pages 1104-1107

  Genc, Gurkan ^a   Kilinc, Veli ^b   Bedir, Abdulkerim ^b   Ozkaya, Ozan ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Cisplatin; Creatine; Drug toxicity; Pioglitazone

Indexed keywords

CISPLATIN; CREATINE; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; DRUG EFFECT; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IC 50; IN VITRO STUDY; INFLAMMATION; KIDNEY CELL; NEPHROTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; CELL LINE; CHEMICALLY INDUCED; DRUG SCREENING; RENAL INSUFFICIENCY;

ANTINEOPLASTIC AGENTS; CELL LINE; CISPLATIN; CREATINE; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPOGLYCEMIC AGENTS; RENAL INSUFFICIENCY; THIAZOLIDINEDIONES;

EID: 84904658317     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2014.926755     Document Type: Article

References (47)

1. Hartmann JT, Lipp H-P. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4:889-901. (Pubitemid 36722480)
2. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460-464. (Pubitemid 37176691)
3. Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol. 2005;22:441-445. (Pubitemid 40993608)
4. Kaushal GP, Kaushal V, Hong X, Shah SV. Role and regulation of activation of caspases in cisplatin induced injury to renal tubular epithelial cells. Kidney Int. 2001;60:1726-1736. (Pubitemid 32999977)
5. Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, Haskins JR. Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int. 1995;48:761-770.
6. Matsushima H, Yonemura K, Ohishi K, Hishida A. The role of oxygen free radicals in cisplatin induced acute renal failure in rats. J Lab Clin Med. 1998;131:518-526. (Pubitemid 28278570)
7. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel). 2010;2:2490-2518.
8. Walker JB. Creatine: biosynthesis, regulation, and function. Adv Enzymol Relat Areas Mol Biol. 1979;50:177-242.
9. Sestili P, Martinelli C, Colombo E, et al. Creatine as an antioxidant. Amino Acids. 2011;40:1385-1396.
10. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-435. (Pubitemid 34177889)
11. Shimazu T, Inoue I, Araki N, et al. A peroxisome proliferator activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke. 2005;36(2):353-359. (Pubitemid 40170822)
12. Haraguchi G, Kosuge H, Maejima Y, et al. Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. Intensive Care Med. 2008;34(7): 1304-1312. (Pubitemid 351904288)
13. Ahmed LA, Salem HA, Attia AS, Agha AM. Pharmacological preconditioning with nicorandil and pioglitazone attenuates myocardial ischemia/reperfusion injury in rats. Eur J Pharmacol. 2011; 663(1-3):51-58.
14. Medhi B, Aggarwal R, Chakrabarti A. Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice. Indian J Exp Biol. 2010;48(8):793-799.
15. Hu H, Zou C, Xi X, Shi Z, Wang G, Huang X. Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice. J Surg Res. 2012;178(1):460-465.
16. Solly K, Wang X, Xu X, Strulovici B, Zheng W. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol. 2004;4:363-372. (Pubitemid 39276278)
17. Atienza JM, Yu N, Kirstein SL, et al. Dynamic and label-free cellbased assays using the real-time cell electronic sensing system. Assay Drug Dev Technol. 2006;4:597-607. (Pubitemid 46017403)
18. Persky AM, Brazeau GA. Clinical pharmacology of dietary supplement Cr monohydrate. Pharmacol Rev. 2001;53:161-176. (Pubitemid 32476115)
19. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460-464. (Pubitemid 37176691)
20. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel). 2010;2:2490-2518.
21. Qian W, Nishikawa M, Haque AM, et al. Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. Am J Physiol Cell Physiol. 2005;289:C1466-C1475. (Pubitemid 41636351)
22. Li S, Wu P, Yarlagadda P, et al. PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol. 2004; 286:F572-F580. (Pubitemid 38233652)
23. Portilla D, Dai G, McClure T, et al. Alterations of PPARalpha and its coactivator PGC-1 in cisplatin-induced acute renal failure. Kidney Int. 2002;62:1208-1218.
24. Kruidering M, Van de Water B, de Heer E, Mulder GJ, Nagelkerke JF. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther. 1997;280: 638-649. (Pubitemid 27171323)
25. Nomura A, Zhang M, SakamotoT, et al. Anti-inflammatory activity of creatine supplementation in endothelial cells in vitro. Br J Pharmacol. 2003;139:715-720. (Pubitemid 36819598)
26. Sharov VG, Saks VA, Kupriyanov VV, et al. Protection of ischemic myocardium by exogenous phosphocreatine. I. Morphologic and phosphorus 31-nuclear magnetic resonance studies. J Thorac Cardiovasc Surg. 1987;94:749-761.
27. Berneburg M, Gremmel T, Kurten V, et al. Creatine supplementation normalizes mutagenesis of mitochondrial DNA as well as functional consequences. J Invest Dermatol. 2005;125:213-220. (Pubitemid 41648152)
28. Kornblum C, Schröder R, Müller K, et al. Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study. Eur J Neurol. 2005;12: 300-309. (Pubitemid 40477138)
29. Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int. 1998;53:394-401. (Pubitemid 28097855)
30. Davis C, Nick H, Agarwal A. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol. 2001;12:2683-2690. (Pubitemid 33115415)
31. Dickey DT, Wu YJ, Muldoon LL, Neuwelt EA. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther. 2005;314:1052-1058. (Pubitemid 41205968)
32. Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology. 2004; 195:221-230. (Pubitemid 38125121)
33. Kroning R, Lichtenstein AK, Nagami GT. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol. 2000;45:43-49. (Pubitemid 30099714)
34. Van Houten VWB, Santos JH. Role of mitochondrial DNA in toxic response to oxidative stress. DNA Rep. 2006;5:145-152. (Pubitemid 43069515)
35. Rico-Sanz J. Creatine reduces human muscle PCr and pH decrements and P(i) accumulation during low-intensity exercise. J Appl Physiol. 2000;88:1181-1191. (Pubitemid 30217413)
36. Walsh B, Tonkonogi M, Soderlund K, Hultman E, Saks V, Sahlin K. The role of phosphorylcreatine and creatine in the regulation of mitochondrial respiration in human skeletal muscle. J Physiol. 2001;537:971-978. (Pubitemid 34026622)
37. Passaquin AC, Renard M, Kay L, et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in MDX mice. Neuromuscul Disord. 2002;12:174-182. (Pubitemid 33152736)
38. Guidi C, Potenza L, Sestili P, et al. Differential effect of creatine on oxidatively-injured mitochondrial and nuclear DNA. Biochim Biophys Acta. 2008;1780:16-26. (Pubitemid 350216949)
39. Sestili P, Martinelli C, Bravi G, et al. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med. 2006;40: 837-849. (Pubitemid 43327318)
40. Wei Q, Dong G, Franklin J, Dong Z. The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int. 2007;72:53-62. (Pubitemid 47014446)
41. Wei-guo Z, Hui Y, Shan L, et al. PPAR-gamma agonist inhibits Ang II-induced activation of dendritic cells via the MAPK and NF-kappaB pathways. Immunol Cell Biol. 2010;88:305-312.
42. Inoue I, Goto S, Matsunaga T, et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001;50:3-11. (Pubitemid 32058541)
43. Hasegawa T, Okada K, Okita Y, Pinsky DJ. Antioxidant properties of pioglitazone limit nicotinamide adenine dinucleotide phosphate hydrogen oxidase and augment superoxide dismutase activity in cardiac allotransplantation. J Heart Lung Transplant. 2011;30: 1186-1196.
44. Kelly GS. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. Altern Med Rev. 2010;15:313-328.
45. Jung YJ, Lee JE, Lee AS, et al. SIRT1 overexpression decreases cisplatin-induced acetylation of NF-kB p65 subunit and cytotoxicity in renal proximal tubule cells. Biochem Biophys Res Commun. 2012;419:206-210.
46. Makino N, Maeda T, Oyama J, Higuchi Y, Mimori K. Improving insulin sensitivity via activation of PPAR-gamma increases telomerase activity in the heart of OLETF rats. Am J Physiol Heart Circ Physiol. 2009;297:2188-2195.
47. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature. 2004;429: 771-776. (Pubitemid 38833129)